enVVeno Medical (NASDAQ:NVNO – Get Rating) and Sigyn Therapeutics (NASDAQ:SIGY – Get Rating) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, valuation, dividends, earnings, institutional ownership and analyst recommendations.
Earnings and Valuation
This table compares enVVeno Medical and Sigyn Therapeutics’ gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|enVVeno Medical||$30,000.00||1,436.28||-$16.53 million||N/A||N/A|
|Sigyn Therapeutics||N/A||N/A||-$3.01 million||N/A||N/A|
Institutional & Insider Ownership
28.8% of enVVeno Medical shares are held by institutional investors. 1.9% of enVVeno Medical shares are held by insiders. Comparatively, 78.5% of Sigyn Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
This is a summary of current ratings for enVVeno Medical and Sigyn Therapeutics, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Sigyn Therapeutics has a consensus target price of $0.93, suggesting a potential upside of 295.74%. Given Sigyn Therapeutics’ higher possible upside, analysts plainly believe Sigyn Therapeutics is more favorable than enVVeno Medical.
This table compares enVVeno Medical and Sigyn Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Risk and Volatility
enVVeno Medical has a beta of 1.37, meaning that its stock price is 37% more volatile than the S&P 500. Comparatively, Sigyn Therapeutics has a beta of -0.92, meaning that its stock price is 192% less volatile than the S&P 500.
enVVeno Medical beats Sigyn Therapeutics on 5 of the 9 factors compared between the two stocks.
About enVVeno Medical (Get Rating)
enVVeno Medical Corporation (Nasdaq: NVNO) is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company’s lead product, the VenoValve®️, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI). Deep venous CVI occurs when valves inside of the deep veins of the leg become damaged, resulting in insufficient blood being returned to the heart. The malfunctioning vein valves cause blood to flow backwards (reflux) and pool in the lower leg, increasing the pressure within the veins of the leg (venous hypertension). In the most severe cases, CVI can lead to venous ulcers (open skin sores) that become chronic and difficult to heal. The VenoValve is implanted in the femoral vein and works as a replacement venous valve, designed to reduce reflux and venous hypertension, and to restore proper directional blood flow back to the heart. With severe deep venous CVI impacting an estimated 2.4 million people in the U.S., who have no effective treatment options, the VenoValve has received Breakthrough Device Designation from the U.S. Food and Drug Administration, and is currently being evaluated in the SAVVE U.S. clinical trial.
About Sigyn Therapeutics (Get Rating)
Sigyn Therapeutics, Inc. operates as a development-stage therapeutic technology company that treats inflammatory conditions by cytokine storm syndrome. It offers Sigyn Therapy, a blood purification technology designed to mitigate cytokine storm syndrome through the broad-spectrum depletion of inflammatory targets from the bloodstream. The company also engages in evaluating the Sigyn Therapy to address CytoVesicles that transport inflammatory cytokine cargos throughout the bloodstream. Sigyn Therapeutics, Inc. was founded in 2019 and is headquartered in San Diego, California.
Receive News & Ratings for enVVeno Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for enVVeno Medical and related companies with MarketBeat.com's FREE daily email newsletter.